On September 9, Moderna, Inc. fell 3.28% in regular trading, trading at $140.795 per share, with turnover of $1.163 billion. The decline came amid broad-based weakness across the biotechnology sector.

The biotech industry saw widespread selling pressure during the session. Among major names, Amgen fell 9.85%, AbbVie declined 2.72%, Ionis Pharmaceuticals dropped 2.79%, and Alnylam Pharmaceuticals lost 1.47%, while Roivant Sciences bucked the trend with an 18.27% gain. Sentiment toward Moderna has also been weighed by a recent downgrade from Rothschild & Co Redburn on September 3, which lowered the stock to Sell from Neutral, setting a price target of $81 — well below the current trading level. Analyst consensus remains at Hold with a mean target of $108, reflecting lingering uncertainty despite the company's breakthrough mRNA cancer vaccine data disclosed in late August, which had previously driven a sharp rally and multiple institutional upgrades.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)